NeuroVasc Technologies is a technology company.
NeuroVasc Technologies has raised $6.0M across 1 funding round.
NeuroVasc Technologies has raised $6.0M in total across 1 funding round.
NeuroVasc Technologies is a California-based medical device startup specializing in the design and development of neurovascular devices, particularly catheter-based technologies for mechanical thrombectomy to treat acute ischemic stroke and other neurovascular diseases. Their product portfolio includes advanced devices such as the eNVi-SR, eNVoke, and eNVac, aimed at improving treatment options for stroke patients globally. With over 100 years of combined expertise among its team, NeuroVasc serves healthcare providers and patients worldwide, operating in more than 35 countries and focusing on expanding access to innovative stroke therapies[1][2][3].
Founded in 2015 in California, NeuroVasc Technologies was established by experts with deep experience in neurovascular device design and development. The idea emerged from the need to improve mechanical thrombectomy solutions for stroke treatment, leveraging catheter-based technology innovations. Early traction included building a strong product pipeline and securing strategic partnerships, such as a $34 million funding agreement with the Wego Group to support clinical trials and product development, marking pivotal moments in their growth[1][2].
NeuroVasc rides the growing trend of advanced minimally invasive neurovascular interventions, addressing the critical need for effective stroke treatments amid rising global stroke incidence. The timing is favorable due to increasing demand for improved mechanical thrombectomy devices and expanding healthcare infrastructure worldwide. Market forces such as aging populations and heightened awareness of stroke outcomes drive adoption. NeuroVasc influences the ecosystem by pushing innovation in catheter-based technologies, contributing to better clinical outcomes and expanding treatment accessibility globally[1][2].
Looking ahead, NeuroVasc is poised to advance its clinical trial programs and expand its product portfolio, supported by recent funding and strategic partnerships. Trends shaping their journey include technological advancements in neurovascular intervention, regulatory approvals, and growing global stroke treatment markets. Their influence is likely to grow as they continue to innovate and scale access to life-saving stroke therapies, reinforcing their role as a dynamic leader in neurovascular device development[1].
NeuroVasc Technologies has raised $6.0M in total across 1 funding round.
NeuroVasc Technologies's investors include Shangbay Capital.
NeuroVasc Technologies has raised $6.0M across 1 funding round. Most recently, it raised $6.0M Series B in May 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2018 | $6.0M Series B | Shangbay Capital |